Program
Tamsulosin
Also written as “tamsulosin hydrochloride”, “Tamsulosin (0.4 mg/j)” and “tamsulosin”.
Its studies are mostly in Prostatic Hyperplasia · Lower Urinary Tract Symptoms · Erectile Dysfunction · Urologic Diseases · Urinary Bladder, Neurogenic, led by 15 companies.
Drug pageTamsulosin: every studyMany companies study it; this page follows only the 56 they lead. All 155 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 140 open or running | phase 4since Sep 18, 2014 | Jun 19, 2006 | none ahead |
| Astellas Pharmaits history only | 100 open or running | phase 4since Mar 17, 2016 | Jul 25, 2007 | none ahead |
| GlaxoSmithKlineits history only | 90 open or running | phase 4since Feb 10, 2011 | Aug 24, 2004 | none ahead |
| Hanmi Pharmaceuticalits history only | 50 open or running | phase 3since Feb 23, 2015 | Sep 4, 2014 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 30 open or running | phase 3since Sep 2, 2015 | Sep 15, 2014 | none ahead |
| Menarini Groupits history only | 33 open or running | phase 1since Jul 22, 2025 | Jul 22, 2025 | none ahead |
| GL Pharm Techits history only | 20 open or running | phase 3since Nov 11, 2014 | Feb 24, 2014 | none ahead |
| Jeil Pharmaceuticalits history only | 20 open or running | phase 3since Nov 21, 2016 | Jul 1, 2014 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 1since Jun 22, 2010 | Jun 22, 2010 | none ahead |
| ADIUMits history only | 10 open or running | no phasesince Jul 7, 2026 | Jul 7, 2026 | none ahead |
| Ascension Healthits history only | 10 open or running | phase 4since Nov 5, 2016 | Nov 5, 2016 | none ahead |
| Dexa Medica Groupits history only | 10 open or running | phase 1since Aug 14, 2024 | Aug 14, 2024 | none ahead |
| Getz Pharmaits history only | 10 open or running | phase 4since Jul 7, 2023 | Jul 7, 2023 | none ahead |
| IlDong Pharmaceuticalits history only | 10 open or running | phase 3since Jul 22, 2016 | Jul 22, 2016 | none ahead |
| NeoTractits history only | 11 open or running | phase 4since Jul 9, 2021 | Jul 9, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Boehringer Ingelheim only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 19, 2006First study: phase 2 study in Urinary Bladder, NeurogenicFirst studyNCT00340704 · 143 enrolled · United States, Belgium, Brazil and more
- Nov 20, 2008Phase 3 study in Urinary Bladder, NeurogenicNCT00796614 · 231 enrolled · United States, Belgium, Brazil and more
- Nov 9, 2012Phase 2 study in Lower Urinary Tract SymptomsNCT01726270 · 689 enrolled · United States
- Sep 18, 20142 phase 2 studiesNCT02244294, NCT02244281
- Sep 18, 20143 phase 4 studies in Prostatic HyperplasiaNCT02244255, NCT02244242, NCT02244229
- Oct 14, 20144 phase 1 studiesNCT02264184, NCT02266537, NCT02266524 and 1 more
- Apr 13, 2015Phase 1 study in Prostatic HyperplasiaNCT02417844 · 34 enrolled
- Oct 1, 2015Phase 3 study in Urological ManifestationsNCT02573311 · 1,117 enrolled · United States
TargetBeta
“Adrenergic receptor alpha-1 antagonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Oxymetazolinerule | AbbVie | phase 4 | 20 |
| Phentolaminerule | opus-genetics-inc | phase 4 | 18 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
| Midodrinerule | Takeda | phase 4 | 10 |
| Prazosinrule | Pfizer | phase 3 | 4 |
Studies
All 14 Boehringer Ingelheim leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02573311Urological Manifestations · United States | 3 | Completed | Aug 1, 2016 | 1,117 |
| NCT02417844Prostatic Hyperplasia | 1 | Completed | May 2015 | 34 |
| NCT02266537Healthy | 1 | Completed | Feb 2006 | 97 |
| NCT02266524Urination Disorders | 1 | Completed | Apr 2005 | 48 |
| NCT02266511Healthy | 1 | Completed | Sep 1999 | 30 |
| NCT02264184Healthy | 1 | Completed | Dec 2008 | 24 |
| NCT02244294Prostatic Hyperplasia | 2 | Completed | Jun 2005 | 176 |
| NCT02244281Lower Urinary Tract Symptoms | 2 | Completed | Nov 2003 | 74 |
| NCT02244255Prostatic Hyperplasia | 4 | Completed | Jun 2000 | 1,993 |
| NCT02244242Prostatic Hyperplasia | 4 | Completed | Aug 1999 | 493 |
| NCT02244229Prostatic Hyperplasia | 4 | Completed | Nov 2000 | 403 |
| NCT01726270Lower Urinary Tract Symptoms · United States | 2 | Completed | Mar 2013 | 689 |
| NCT00796614Urinary Bladder, Neurogenic · United States, Belgium, Brazil and more | 3 | Completed | Feb 2009 | 231 |
| NCT00340704Urinary Bladder, Neurogenic · United States, Belgium, Brazil and more | 2 | Completed | Jun 2009 | 143 |
How it is read
Names in the registry
- “Tamsulosin”, 12 entries
- “tamsulosin hydrochloride”, 6 entries
- “Tamsulosin (0.4 mg/j)”, 5 entries
- “tamsulosin”, 4 entries
- “HIP1402”, 3 entries
Conditions, from the studies’ own filings
- Prostatic Hyperplasia, 22 studies
- Lower Urinary Tract Symptoms, 6 studies
- Erectile Dysfunction, 3 studies
- Urologic Diseases, 2 studies
- Urinary Bladder, Neurogenic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.